Antiviral activity of cyclosaligenyl prodrugs of the nucleoside analogue bromovinyldeoxyuridine against herpes viruses

International Journal of Antimicrobial Agents

Volumn 27, Issue 5, 2006, Pages 423-430

  Meerbach, Astrid ^a   Meier, Chris ^b   Sauerbrei, Andreas ^a   Meckel, Heide Marie ^a   Wutzler, Peter ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b UNIVERSITY OF HAMBURG   (Germany)

Author keywords

Antivirals; Brivudin; cycloSal prodrugs; EBV; HSV; VZV

Indexed keywords

3 METHYL CYCLOSAL 3' BROMOVINYLDEOXYURIDINE MONOPHOSPHATE; 3 METHYL CYCLOSAL 3' O ACETYLBROMOVINYLDEOXYURIDINE MONOPHOSPHATE; 3 METHYL CYCLOSAL 3' O DECANOYLBROMOVINYLDEOXYURIDINE MONOPHOSPHATE; 3 METHYL CYCLOSAL 3' O DEXTRO ALANINYLBROMOVINYLDEOXYURIDINE MONOPHOSPHATE; 3 METHYL CYCLOSAL 3' O DEXTRO ISOLEUCINYLBROMOVINYLDEOXYURIDINE MONOPHOSPHATE; 3 METHYL CYCLOSAL 3' O DEXTRO LEUCINYLBROMOVINYLDEOXYURIDINE MONOPHOSPHATE; 3 METHYL CYCLOSAL 3' O DEXTRO PHENYLALINYLBROMOVINYLDEOXYURIDINE MONOPHOSPHATE; 3 METHYL CYCLOSAL 3' O DEXTRO PROLINYLBROMOVINYLDEOXYURIDINE MONOPHOSPHATE; 3 METHYL CYCLOSAL 3' O DEXTRO VALINYLBROMOVINYLDEOXYURIDINE MONOPHOSPHATE; 3 METHYL CYCLOSAL 3' O GLYCINYLBROMOVINYLDEOXYURIDINE MONOPHOSPHATE; 3 METHYL CYCLOSAL 3' O HEXANOYLBROMOVINYLDEOXYURIDINE MONOPHOSPHATE; 3 METHYL CYCLOSAL 3' O IBUTERYLBROMOVINYLDEOXYURIDINE MONOPHOSPHATE; 3 METHYL CYCLOSAL 3' O LEVO ALANINYLBROMOVINYLDEOXYURIDINE MONOPHOSPHATE; 3 METHYL CYCLOSAL 3' O LEVO ISOLEUCINYLBROMOVINYLDEOXYURIDINE MONOPHOSPHATE; 3 METHYL CYCLOSAL 3' O LEVO LEUCINYLBROMOVINYLDEOXYURIDINE MONOPHOSPHATE; 3 METHYL CYCLOSAL 3' O LEVO PHENYLALINYLBROMOVINYLDEOXYURIDINE MONOPHOSPHATE; 3 METHYL CYCLOSAL 3' O LEVO PROLINYLBROMOVINYLDEOXYURIDINE MONOPHOSPHATE; 3 METHYL CYCLOSAL 3' O LEVO VALINYLBROMOVINYLDEOXYURIDINE MONOPHOSPHATE; 3 METHYL CYCLOSAL 3' O LEVULINYLBROMOVINYLDEOXYURIDINE MONOPHOSPHATE; 3 METHYL CYCLOSAL 3' O METHYLBROMOVINYLDEOXYURIDINE MONOPHOSPHATE; 3 METHYL CYCLOSAL 3' O PIVALOYLBROMOVINYLDEOXYURIDINE MONOPHOSPHATE; 3 METHYL CYCLOSAL 3' O PROPIONYLBROMOVINYLDEOXYURIDINE MONOPHOSPHATE; 5 (2 BROMOVINYL) 2' DEOXYCYTIDINE; 5 H CYCLOSAL 3' O ACETYLBROMOVINYLDEOXYURIDINE MONOPHOSPHATE; 5 H CYCLOSAL 3' O IBUTYRYLBROMOVINYLDEOXYURIDINE MONOPHOSPHATE; ACICLOVIR; ANTIVIRUS AGENT; GANCICLOVIR; NUCLEOSIDE ANALOG; UNCLASSIFIED DRUG; UNINDEXED DRUG; BROXURIDINE; DRUG DERIVATIVE; PRODRUG;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; DNA HYBRIDIZATION; EPSTEIN BARR VIRUS; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HERPES VIRUS; HUMAN; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; MASKING; NITROBLUE TETRAZOLIUM TEST; NONHUMAN; PHOSPHORYLATION; PRIORITY JOURNAL; TARGET CELL; VARICELLA ZOSTER VIRUS; VIRUS REPLICATION; CELL CULTURE; CHEMICAL STRUCTURE; CHEMISTRY; CYTOPATHOGENIC EFFECT; DOSE RESPONSE; DRUG EFFECT; FIBROBLAST; PHYSIOLOGY; VIROLOGY; VIRUS CULTURE;

ANTIVIRAL AGENTS; BROMODEOXYURIDINE; CELLS, CULTURED; CYTOPATHOGENIC EFFECT, VIRAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBROBLASTS; HERPESVIRIDAE; HUMANS; MOLECULAR STRUCTURE; PLAQUE ASSAY; PRODRUGS;

EID: 33646148053     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2005.11.021     Document Type: Article

References (45)

1. Elion G.B., Furman P.A., Fyfe J.A., de Miranda P., Beauchamp L., and Schaeffer H.J. Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl)guanine. Proc Natl Acad Sci USA 74 (1977) 5716-5720
2. Wagstaff A., Faulds D., and Goa K.L. Aciclovir: a reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs 47 (1994) 153-205
3. De Clercq E. Trends in the development of new antiviral agents for the chemotherapy of infections caused by herpesviruses and retroviruses. Rev Med Virol 5 (1995) 149-164
4. Ciancio G., Burke G.W., Mattiazzi A., et al. Cytomegalovirus prophylaxis with valganciclovir in kidney, pancreas-kidney, and pancreas transplantation. Clin Transplant 4 (2004) 402-406
5. De Clercq E. Antiviral drugs: current state of the art. J Clin Virol 22 (2001) 73-89
6. Hsu J.L., and Glaser S.L. Epstein-Barr virus-associated malignancies: epidemiologic patterns and etiologic implications. Crit Rev Oncol Hematol 34 (2000) 27-53
7. Colby B.M., Shaw J.E., Elion G.B., and Pagano J.S. Effect of acyclovir [9-(2-hydroxyethoxymethyl)-guanine] on Epstein-Barr virus DNA replication. J Virol 34 (1980) 560-568
8. Lin J.C., Smith M.C., and Pagano J.S. Prolonged inhibitory effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine against replication of Epstein-Barr virus. J Virol 50 (1984) 50-55
9. Lin J.C., De Clercq E., and Pagano J.S. Inhibitory effects of acyclic nucleoside phosphonate analogs, including (S)-1-(3-hydroxy-2-phosphonyl-methoxypropyl)-cytosine, on Epstein-Barr virus replication. Antimicrob Agents Chemother 35 (1991) 2440-2443
10. Englund J.A., Zimmermann M.E., Swierkosz E.M., Goodman J.L., Scholl D.R., and Balfour H.H. Herpes simplex virus resistant to acyclovir. A study in a tertiary care center. Ann Intern Med 112 (1990) 416-422
11. Chatis P.A., and Crumpacker C.S. Resistance of herpesvirus to antiviral drugs. Antimicrob Agents Chemother 36 (1992) 1589-1595
12. Reyes M., Graber J.M., Weatherall N., Hodges-Savola C., Reeves W.C., and The Task Force on herpesvirus resistance. Acyclovir-resistant herpes simplex virus: preliminary results from a national surveillance system. Antiviral Res 37 (1998) A44/16
13. Limaye A.P., Raghu G., Koelle D.M., Ferrenberg J., Huang M.L., and Boeckh M. High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy. J Infect Dis 186 (2002) 724-725
14. Kimberlin D.W., and Whitley R.J. Antiviral resistance: mechanisms, clinical significance, and future implications. J Antimicrob Chemother 37 (1996) 403-421
15. Meier C. Pro-nucleotides-recent advances in the design of efficient tools for the delivery of biologically active nucleoside monophosphates. Synlett (1998) 233-242
16. Meier C., Knispel T., Lorey M., and Balzarini J. CycloSal-pro-nucleotides: the design and biological valuation of a new class of lipophilic nucleotide prodrugs. Int Antiviral News 5 (1997) 183-185
17. Meier C. cycloSal-pronucleotides-design of chemical trojan horses. Mini Rev Med Chem 2 (2002) 219-234
18. Meier C., Meerbach A., and Balzarini J. CycloSal-pronucleotides-development of first and second generation chemical trojan horses for antiviral chemotherapy. Front Biosci 9 (2004) 873-890
19. Meier C., Lomp A., Meerbach A., and Wutzler P. Synthesis, hydrolysis and anti-EBV activity of a series of 3′-modified cycloSal-BVDUMP pronucleotides. Nucleosides Nucleotides Nucleic Acids 20 (2001) 307-314
20. Meier C., Lomp A., Meerbach A., and Wutzler P. CycloSal-BVDUMP pronucleotides-how to convert an anti-EBV-inactive nucleoside analogue into a bioactive compound. J Med Chem 45 (2002) 5157-5172
21. Meier C., Meerbach A., and Wutzler P. CycloSal-pronucleotides of brivudine monophosphate-highly active antiviral agents. Curr Med Chem Anti-Infect Agents 4 (2005) 317-335
22. Klöcking R., Schacke M., and Wutzler P. Primärscreening antiherpetischer Verbindungen mit EZ4U. Chemother J 4 (1995) 141-147
23. Pauwels R., Balzarini J., Baba M., et al. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J Virol Methods 20 (1988) 309-321
24. Lin J.-C., Shaw J.E., Smith M.C., and Pagano J.S. Effect of 12-O-tetra-decanoylphorbol-13-acetate on the replication of Epstein-Barr virus. I. Characterization of viral DNA. Virology 99 (1979) 183-187
25. Meerbach A., Holy A., Wutzler P., De Clercq E., and Neyts J. Inhibitory effects of novel nucleoside and nucleotide analogues on Epstein-Barr virus replication. Antivir Chem Chemother 9 (1998) 275-282
26. Emanuel J.R. Simple and efficient system for synthesis of non-radioactive nucleic acid hybridization probes using PCR. Nucleic Acids Res 19 (1991) 2790
27. Meier C., Lorey M., De Clercq E., and Balzarini J. cycloSal-2′,3′-dideoxy-2′,3′-didehydrothymidine monophosphate (cycloSal-d4TMP): synthesis and antiviral evaluation of a new d4TMP delivery system. J Med Chem 41 (1998) 1417-1427
28. Meier C., Knispel T., De Clercq E., and Balzarini J. cycloSal-pro-nucleotides (cycloSal-NMP) of 2′,3′-dideoxyadenosine (ddA) and 2′,3′-dideoxy-2′,3′-didehydroadenosine (d4A): synthesis and antiviral evaluation of a highly efficient nucleotide delivery system. J Med Chem 42 (1999) 1604-1614
29. Meier C., Knispel T., Marquez V.E., Siddiqui M.A., De Clerq E., and Balzarini J. cycloSal-pro-nucleotides of 2′-fluoro-ara- and 2′-fluoro-ribo-2′,3′-dideoxyadenosine (F-ara- and F-ribo-ddA) as a strategy to bypass a metabolic blockade. J Med Chem 42 (1999) 1615-1624
30. Balzarini J., Haller-Meier F., De Clercq E., and Meier C. Antiviral activity of cyclosaligenyl prodrugs of acyclovir, carbovir and abacavir. Antivir Chem Chemother 12 (2002) 302-306
31. Meier C., Habel L., Haller-Meier F., et al. Chemistry and anti-herpes simplex virus type 1 evaluation of cycloSal-nucleotides of acyclic nucleoside analogues. Antivir Chem Chemother 9 (1998) 389-402
32. Meerbach A., Klöcking R., Meier C., Lomp A., Helbig B., and Wutzler P. Inhibitory effect of cyclosaligenyl-nucleoside monophosphates (cycloSal-NMP) of acyclic nucleoside analogues on HSV-1 and EBV. Antiviral Res 45 (2000) 69-77
33. Meerbach A., Klöcking R., Friedrichs C., Wutzler P., and Meier C. Antivirale Wirkung von cycloSaligenyl-Pro-Nucleotiden gegen das Herpes-simplex-Virus und Epstein-Barr-Virus. Chemotherapie Journal 12 (2003) 79-84
34. Lomp A., Meier C., Herderich M., and Wutzler P. Evidence for cyclophosphate formation during hydrolysis of 3-methyl-cycloSal-PCVMP. Nucleosides Nucleotides 18 (1999) 943-944
35. Balzarini J., Bernaerts R., Verbruggen A., and De Clercq E. Role of the incorporation of (E)-5-(2-iodovinyl)-2′-deoxyuridine and its carbocyclic analogue into DNA of herpes simplex virus type 1-infected cells in the antiviral effects of these compounds. Mol Pharmacol 37 (1990) 402-407
36. Roberts G.B., Fyfe J.A., McKee S.A., et al. Varicella-zoster virus thymidine kinase characterization and substrate specificity. Biochem Pharmacol 46 (1993) 2209-2218
37. Degreve B., Andrei G., Izquierdo M., et al. Varicella-zoster virus thymidine kinase gene and antiherpetic pyrimidine nucleoside analogues in a combined gene/chemotherapy treatment of cancer. Gene Ther 4 (1997) 1107-1114
38. Hovi T. Successful selective inhibitors of viruses. In: Field H.J. (Ed). Antiviral agents: the development and assessment of antiviral chemotherapy Vol. 1 (1988), CRC Press Inc., Boca Raton, FL
39. Fyfe J.A. Differential phosphorylation of (E)-5-(2-bromovinyl)-2′-deoxyurdine monophosphate by thymidylate kinases from herpes simplex viruses types 1 and 2 and varicella zoster virus. Mol Pharmacol 21 (1982) 432-437
40. Meier C., Lomp A., Meerbach A., and Wutzler P. cycloSaligenyl-5-[(E)-2-bromovinyl]-2′-deoxyuridine monophosphate (cycloSal-BVDUMP) pronucleotides active against Epstein-Barr virus. Chembiochem 4 (2001) 283-285
41. Lin J.C., Smith M.C., and Pagano J.S. Comparative efficacy and selectivity of some nucleoside analogs against Epstein-Barr virus. Antimicrob Agents Chemother 27 (1985) 971-973
42. Lin J.C., Smith M.C., Choi E.I., De Clercq E., Verbruggen A., and Pagano J.S. Effect of (E)-5-(2-bromovinyl)-2′-deoxyuridine on replication of Epstein-Barr virus in human lymphoblastoid cell lines. Antiviral Res 5 Suppl. 1 (1985) 121-126
43. Pagano J.S. Epstein-Barr virus: therapy of active and latent infection. In: Jeffries D.J., and De Clercq E. (Eds). Antiviral chemotherapy (1995), John Wiley & Sons, Chichester, UK
44. Littler E., Zeuthen J., McBride A.A., et al. Identification of an Epstein-Barr virus-coded thymidine kinase. EMBO J 5 (1986) 1959-1966
45. Gustafson E.A., Chillemi A.C., Sage D.R., and Fingeroth J.D. The Epstein-Barr virus thymidine kinase does not phosphorylate ganciclovir or acyclovir and demonstrates a narrow substrate specificity compared to the herpes simplex virus type 1 thymidine kinase. Antimicrob Agents Chemother 42 (1998) 2923-2931